COVID-19 research roundup: Blood cell damage, poor lung function, underreporting in the US,

The following is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Low oxygen levels may be due to blood cell damage

Damage done by the coronavirus to the membranes of red blood cells that carry oxygen may explain why many COVID-19 patients have alarmingly low oxygen levels, according to new research. Specifically, the virus attacks the membranes’ most abundant protein, called band 3, said senior researcher Angelo D’Alessandro of the University of Colorado Anschutz Medical Campus. The protein is critical to stabilize red cell membrane structures, regulate red cell metabolism and stabilize the cell’s processing of hemoglobin, the substance that transports and then releases the oxygen. [caption id=“attachment_6179371” align=“alignnone” width=“1280”] Illustration of red blood cells lookin’ fine and healthy.[/caption] By disrupting the interaction of band 3 with hemoglobin, the virus could impair red cells’ capacity to deliver oxygen, D’Alessandro said. “Since red cells circulate for up to 120 days, this could also help explain why it can take months to recover from the virus … until enough new red cells without this damage are made and circulate,” D’Alessandro told Reuters, adding that he became infected in March. “It took me three weeks to heal from the infection, but I am still recovering slowly,” he said. D’Alessandro’s team posted their findings on Tuesday on medRxiv, ahead of peer review.

Experimental vaccines show promise in small early trials

Two experimental coronavirus vaccines appear to be safe and have yielded promising results in small, early-stage clinical trials. The vaccines are among 17 already being tested in humans. One, being developed by Inovio Pharmaceuticals Inc, induced immune responses in 34 of 36 healthy volunteers, Inovio said on Tuesday, based on their levels of virus-neutralizing antibodies and T-cell responses – two metrics considered vital for a successful vaccine. On Wednesday, Pfizer Inc and Germany’s BioNTech said that 24 healthy volunteers who received their BNT162b1 vaccine developed higher levels of COVID-19 antibodies than typically seen in those who had been infected by 28 days after receiving doses. Both vaccines will move onto much larger trials that could demonstrate whether the early immune responses translate into protection against the virus. An effective vaccine is seen as vital to ending the pandemic.

Lung function remains poor after COVID-19 hospitalization

Abnormal lung function may continue long after COVID-19 patients are released from the hospital, new data confirms. Doctors in China tracked 57 patients – including 17 who had been severely ill – by repeatedly testing lung function after they went home from the hospital. At 30 days, more than half still had abnormal-looking lungs on CT scans, and three-fourths had abnormal lung function tests, the researchers reported in Respiratory Research. Tests that show how much oxygen is traveling from the lungs to the bloodstream were still abnormal in about 76 percent of patients who had been severely ill and in nearly 43 percent of those recovering from moderate illness.

Coronavirus deaths likely higher than reported in US

The number of Americans who died of COVID-19 from March through May was likely significantly higher than the official count, US researchers say. The difference was likely due in part to state-level reporting discrepancies, they said. Overall, the National Center for Health Statistics tallied 781,000 deaths from any cause during the three months, or 1,22,300 more than the historical average. But the number officially attributed to COVID-19 was 95,235 – leaving 28 percent of the excess deaths unexplained, according to a report on Wednesday in JAMA Internal Medicine. In some cases, deaths that occurred before tests for COVID-19 were widely available might have been due to the coronavirus, researchers said. COVID-19 death reporting discrepancies have decreased in recent weeks as diagnostic testing became more available and awareness of the illness has grown, study leader Daniel Weinberger from the Yale School of Public Health told Reuters. “Things are much better now than they were in March,” he said. [caption id=“attachment_8549071” align=“alignnone” width=“1280”] Blood testing for a COVID-19 test may not be necessary with alternatives, like medical devices and wearables, tracking secondary indicators more accurately.[/caption]

Advanced devices coming to track signs of COVID-19

Noninvasive tools for continuously diagnosing and tracking coronavirus infections, not only in the hospital but also at home, are on the way, researchers say in an editorial published on Wednesday in Science Advances. Some involve consumer-grade wearables, but medical-grade devices that predict, monitor, and track COVID-19 with far greater accuracy are being tested, they said. One is a wireless patch worn on the base of the neck that senses cough frequency and intensity, breathing rate and effort, wheezing and sneezing, along with heart rate, heart sounds and skin temperature. The patch is being used in nursing homes to track those most vulnerable, according to the report. Pilot studies testing similar tools in COVID-19 patients in the hospital and at home have revealed “many interesting features of the disease and its progression,” the authors say. They believe the new devices will help detect COVID-19 symptoms early in the general population, recognize the need for an escalation of care, and track recovery curves. Also read:  **Life after coronavirus: A look at what recovery from COVID-19 may look like for many survivors**